pro 5.4 software (SoftMax Inc)
90
Structured Review
SoftMax Inc
pro 5.4 software
Pro 5.4 Software, supplied by SoftMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+5%2E4+software/pro+5+software/pm39753170-104-23-23
Average 90 stars, based on 1 article reviews
Pro 5.4 Software, supplied by SoftMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+5%2E4+software/pro+5+software/pm39753170-104-23-23
Average 90 stars, based on 1 article reviews
pro 5.4 software - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Generated:Article Title: A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. Article Snippet: Article history: Received 16 September 2015 Received in revised form 7 December 2015 Accepted 29 December 2015 Available online xxxx Background: Programmed cell death ligand-1 (PD-L1) with its receptor PD-1 pathway is overactivated in many tumors.. Inhibiting the interaction of PD-L1 and PD-1 is an attractive strategy to restore tumor-specific T cell immunity for tumor therapy.. Methods: A fully human anti-PD-L1 monoclonal antibody (mAb) B60-55 was identified by yeast surface display. Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: Data were acquired with Article Title: Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisited Article Snippet: Data were acquired using the Article Title: Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy. Article Snippet: Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients.. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target.. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC). Article Title: Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Article Snippet: The initial velocity 154 was calculated as the change in absorbance per min (mUabs/min) of the reaction as determined using Article Title: Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis Article Snippet: The initial velocity was calculated as the change in absorbance per min (mU abs /min) of the reaction as determined using Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: The change in dye fluorescence was recorded for 240 s with Article Title: Antigen-Specific Immune Modulation Targets mTORC1 Function to Drive Chemokine Receptor-Mediated T Cell Tolerance Article Snippet: The OD 450 was read on a SpectraMax 190 counter (Molecular Devices, Sunnyvale, CA) and analyzed using Software:Article Title: A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. Article Snippet: Article history: Received 16 September 2015 Received in revised form 7 December 2015 Accepted 29 December 2015 Available online xxxx Background: Programmed cell death ligand-1 (PD-L1) with its receptor PD-1 pathway is overactivated in many tumors.. Inhibiting the interaction of PD-L1 and PD-1 is an attractive strategy to restore tumor-specific T cell immunity for tumor therapy.. Methods: A fully human anti-PD-L1 monoclonal antibody (mAb) B60-55 was identified by yeast surface display. Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: Data were acquired with Article Title: Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisited Article Snippet: Data were acquired using the Article Title: Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy. Article Snippet: Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients.. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target.. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC). Article Title: Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Article Snippet: The initial velocity 154 was calculated as the change in absorbance per min (mUabs/min) of the reaction as determined using Article Title: Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis Article Snippet: The initial velocity was calculated as the change in absorbance per min (mU abs /min) of the reaction as determined using Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: The change in dye fluorescence was recorded for 240 s with Article Title: Antigen-Specific Immune Modulation Targets mTORC1 Function to Drive Chemokine Receptor-Mediated T Cell Tolerance Article Snippet: The OD 450 was read on a SpectraMax 190 counter (Molecular Devices, Sunnyvale, CA) and analyzed using Fluorescence:Article Title: A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. Article Snippet: Article history: Received 16 September 2015 Received in revised form 7 December 2015 Accepted 29 December 2015 Available online xxxx Background: Programmed cell death ligand-1 (PD-L1) with its receptor PD-1 pathway is overactivated in many tumors.. Inhibiting the interaction of PD-L1 and PD-1 is an attractive strategy to restore tumor-specific T cell immunity for tumor therapy.. Methods: A fully human anti-PD-L1 monoclonal antibody (mAb) B60-55 was identified by yeast surface display. Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: Data were acquired with Article Title: Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisited Article Snippet: Data were acquired using the Article Title: Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy. Article Snippet: Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients.. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target.. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC). Article Title: Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Article Snippet: The initial velocity 154 was calculated as the change in absorbance per min (mUabs/min) of the reaction as determined using Article Title: Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis Article Snippet: The initial velocity was calculated as the change in absorbance per min (mU abs /min) of the reaction as determined using Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: The change in dye fluorescence was recorded for 240 s with Article Title: Antigen-Specific Immune Modulation Targets mTORC1 Function to Drive Chemokine Receptor-Mediated T Cell Tolerance Article Snippet: The OD 450 was read on a SpectraMax 190 counter (Molecular Devices, Sunnyvale, CA) and analyzed using Concentration Assay:Article Title: A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. Article Snippet: Article history: Received 16 September 2015 Received in revised form 7 December 2015 Accepted 29 December 2015 Available online xxxx Background: Programmed cell death ligand-1 (PD-L1) with its receptor PD-1 pathway is overactivated in many tumors.. Inhibiting the interaction of PD-L1 and PD-1 is an attractive strategy to restore tumor-specific T cell immunity for tumor therapy.. Methods: A fully human anti-PD-L1 monoclonal antibody (mAb) B60-55 was identified by yeast surface display. Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: Data were acquired with Article Title: Key phosphorylation sites for robust β-arrestin2 binding at the MOR revisited Article Snippet: Data were acquired using the Article Title: Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy. Article Snippet: Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients.. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target.. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC). Article Title: Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Article Snippet: The initial velocity 154 was calculated as the change in absorbance per min (mUabs/min) of the reaction as determined using Article Title: Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis Article Snippet: The initial velocity was calculated as the change in absorbance per min (mU abs /min) of the reaction as determined using Article Title: A bead-based GPCR phosphorylation immunoassay for high-throughput ligand profiling and GRK inhibitor screening Article Snippet: The change in dye fluorescence was recorded for 240 s with Article Title: Antigen-Specific Immune Modulation Targets mTORC1 Function to Drive Chemokine Receptor-Mediated T Cell Tolerance Article Snippet: The OD 450 was read on a SpectraMax 190 counter (Molecular Devices, Sunnyvale, CA) and analyzed using |